Shopping cart

There are no products in your shopping cart.

0 Items $0.00

User login

MesoTotal™ HPC/HSC Differentiation System

MesoTotal™ for differentiation of hematopoietic stem and progenitor cells
MesoTotal™ HPC/HSC Differentiation System
Prod. No.

Primorigen Biosciences’ MesoTotal™ HPC/HSC Differentiation System combines a patent-pending medium formulation and novel protocol for robust differentiation of human pluripotent stem cells (hPSCs) into hematopoietic progenitor cells (CD45/43+, and CD34+) and hematopoietic stem cells (CD45/43+, CD34+, CD38-, CD45RA-, CD90+). The MesoTotal™ Differentiation System uses a simple two-step incubation procedure and does not require feeder cell co-culturing. MesoTotal™ recently was used in a Stem Cell Reports publication (Ronn et al, 2015) to help establish that selective inhibition of retinoic acid signaling maintains a more primitive phenotype of generated hematopoietic progenitors with enhanced Lymphoid and Myeloid differentiation capacity. Additionally, MesoTotal™ HPC/HSC Differentiation Medium demonstrated improved primitive hematopoietic progenitor cell production from the hiPSC line RB9-CB1 derived from cord blood endothelial cells and the hESC lines H1 and HUES3.

Kit Components

  • 80 ml MesoTotal™ Differentiation Medium
  • 10cm Prequalified Suspension Plates
  • Detailed User Protocol


  • Pre-made, thaw and use
  • Validated across iPSC (RB9-CB1) and hESC lines (H1 and HUES3)
  • Emerging cells possess lymphoid and myeloid differentiation capability
  • Colony forming unit (CFU) numbers approach those obtained from cord blood
  • Compatible with Primorigen’s Vitronectin XF™ substrate

MesoTotal for enhanced production of HSCs and HPCs

1: Daley et al Ann NY Acad Sci. 2009 September; 1176:219-227

Hematopoietic Progenitor & Stem Cells

FACS comparison of HPC and HSC phenotypic markers for MesoTotal™ generated blood cells (top row) and cord blood CD34+ cells (bottom row). MesoTotal™ generated greater than 70% CD45/43+, CD34+ progenitors (top, left). MesoTotal™ also generated a comparable number of phenotypic HSCs (CD45/43+, CD34+, CD38-, CD45RA-, CD90+) as were present in the cord blood isolated control (top and bottom, right, respectively). Note the profile similarities between phenotypic HPCs (top and bottom, left) and phenotypic HSCs (top and bottom, right).

Differentiation & CFUs

Progenitors (CD45/43+, CD34+) were differentiated into mature myeloid and erythroid cells (left images). The graph (right) shows MesoTotal™ produced HPCs return numbers of CFU’s that approach those obtained from cord blood control HPCs.

HSC Differentiation: Days 0-7

Day 0 (left) dense human iPSC colonies on MEFs before lifting. Day 0 (middle) Lifted colonies suspended in standard EB medium. Day 7 (right) developing EBs in 100% MesoTotal™.

HSC Differentiation: Days 8-16

Day 12 (left) Plated, cystic EBs showing early endothelial-like spread. Day 16 (middle and right), clusters of emerging hematopoietic cells characteristic of high hematopoietic cell yield.